Last reviewed · How we verify
Pharmacological cardioversion with Amiodarone
At a glance
| Generic name | Pharmacological cardioversion with Amiodarone |
|---|---|
| Also known as | Amiodarone |
| Sponsor | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis
- Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter (PHASE4)
- Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation (PHASE4)
- Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling (NA)
- Cerebral Oxygen Saturation Measurement During Cardioversion Because of Atrial Fibrillation (NA)
- Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study (PHASE4)
- Therapy of Atrial Flutter by Afib Ablation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: